Pfizer's Lyme Vaccine Achieves Over 70% Efficacy in Phase 3, Regulatory Filings Planned
PFE sits 27% above its 52-week low of $20.915.
Summary
Pfizer and Valneva reported positive topline results from their Phase 3 trial for the LB6V Lyme disease vaccine candidate, demonstrating over 70% efficacy in preventing the disease and good tolerability. Despite a statistical criterion not being met in the primary endpoint due to fewer cases than anticipated, the criterion was met in a second pre-specified analysis, and Pfizer expressed confidence in the vaccine's potential. This development is significant for Pfizer, a large-cap pharmaceutical company, as it represents a potential new revenue stream in an area with no currently approved human vaccine. The companies are planning submissions to regulatory authorities, which could lead to the first-to-market solution for Lyme disease. Traders will closely watch the regulatory approval process and subsequent commercialization plans.
At the time of this announcement, PFE was trading at $26.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $153.4B. The 52-week trading range was $20.92 to $27.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.